Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Advances in Arrhythmia and Electrophysiology
    • Challenge of the Week
    • Journal Update
    • Late-Breaking Clinical Trial Results
    • Podcast Archive
    • Teaching Rounds in Cardiac Electrophysiology
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation:
Arrhythmia and Electrophysiology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Advances in Arrhythmia and Electrophysiology
    • Challenge of the Week
    • Journal Update
    • Late-Breaking Clinical Trial Results
    • Podcast Archive
    • Teaching Rounds in Cardiac Electrophysiology
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Drug-Induced Arrhythmias, Precision Medicine, and Small Data

Glenn I. Fishman
Download PDF
https://doi.org/10.1161/CIRCEP.117.005208
Circulation: Arrhythmia and Electrophysiology. 2017;10:e005208
Originally published April 13, 2017
Glenn I. Fishman
From the Leon H. Charney Division of Cardiology, NYU School of Medicine, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics

Jump to

  • Article
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
Loading
  • Editorials
  • arrhythmias
  • azithromycin
  • basic science research
  • electrophysiology
  • ion channels/membrane transport
  • precision medicine

Precision medicine refers to new treatment and prevention strategies that take individual variability into account.1 Toward that end, the National Institutes of Health Precision Medicine Initiative envisions supporting a research program to encourage creative approaches to precision medicine, test them rigorously, and ultimately use them to build the evidence base needed to guide clinical practice.2 A major component of the Precision Medicine Initiative is the National Institutes of Health All of Us Research Program, which will engage ≥1 million volunteers living in the United States to contribute their health data over many years to improve health outcomes, fuel the development of new treatments for disease, and catalyze a new era of evidence based and more precise preventive care and medical treatment.3

See Article by Yang et al

The variable clinical response to drug therapy provides an especially compelling case for the promise of the precision medicine paradigm. A significant proportion of individuals treated with drugs display either little benefit, or even more problematic, develop serious and sometimes life-threatening adverse effects. Indeed, in 2014, as many as 253 017 serious outcomes, including 123 927 deaths, were reported through the Federal Drug Administration Adverse Events Reporting System.4 Among the more devastating adverse drug effects, seen with both antiarrhythmic and noncardiac drugs, are proarrhythmia and sudden cardiac death. The recognition of this problem has significantly impacted the drug development paradigm5,6 and led to the withdrawal or disapproval of numerous noncardiac medications from the United States and European markets—including astemizole, cisapride, sertindole, and terodiline.

Azithromycin is a macrolide antibiotic and the most commonly prescribed antibiotic in the United States. Indeed, with over 52 million prescriptions written in 2010, it was the sixth most common medication prescribed in any class. In 2012, based on a retrospective analysis of the Tennessee Medicaid cohort, Ray et al7 reported that patients who took azithromycin compared with propensity-score–matched individuals who took no antibiotics or who took amoxicillin, ciprofloxacin, or levofloxacin had a small, but statistically significant increased risk of cardiovascular death. Accordingly, later that same year, the Federal Drug Administration issued a warning to consider the risk of fatal arrhythmias before prescribing azithromycin, especially in those individuals with risk factors for proarrhythmias, including prolonged QT, other medications that are likely to prolong the QT interval, or those with a history of torsade, arrhythmias, or uncompensated heart failure.8

How do we move from detection of small but real signals found in exceedingly large data sets (big data) to prospectively identifying the relatively rare individuals who are at risk of developing life-threatening proarrhythmic effects? For the time being, at least part of the answer is through detailed mechanistic studies of the underlying biology—in this case studies of ion channel behavior and cardiac electrophysiology—a strategy that could fondly be called small data.

In this issue of Circulation Arrhythmia and Electrophysiology, Yang et al9 describe a novel proarrhythmic syndrome associated with azithromycin therapy. The patient, a young black woman with no relevant past medical history, took a 5-day course of azithromycin for an upper respiratory infection. One day after completing the course of therapy, she developed recurrent episodes of syncope that were attributable to rapid polymorphic runs of ventricular tachycardia. The patient was taking no other medications, the QT interval was normal, and there was no evidence of structural heart disease based on a cardiac magnetic resonance imaging. The episodes of ventricular tachycardia resolved over 3 days. Whole-exome sequencing did not identify any rare nonsynonymous variants in known inherited arrhythmia syndrome genes.

The molecular mechanisms responsible for proarrhythmogenic adverse drug responses are legion.10 Most commonly, however, the proarrhythmic behavior is a consequence of drug-dependent block of repolarizing currents, especially binding to and block of hERG, which is responsible for the cardiac IKr current.11,12 Reductions in IKr lead to QT prolongation and increased propensity for torsade de pointes. From over a decade of genetic studies, we have learned that sequence variants in the genes encoding hERG or its ancillary partners KCNE2 and KCNE1 may increase susceptibility to drug-induced arrhythmias.13 Viewed in a larger context, variability in one or several genetic determinants of pharmacokinetics and pharmacodynamics, or more globally, variability in the integrated behavior of multicomponent networks of proteins that ultimately influence drug availability and response may play also influence proarrhythmia susceptibility.14

However, in this case, given the lack of QT prolongation, the authors of the study used multiple complementary strategies to identify other potential mechanisms of proarrhythmia. These included measuring the ECG response in conscious mice challenged with azithromycin, analysis of excitability, and action potential parameters in the cardiac-like HL-1 cell line, patch-clamp studies of Na+ currents (peak and late) and delayed rectifier IKr K+ currents in transfected human embryonic kidney cells, and patch-clamp studies of L-type and T-type Ca2+ currents in primary rabbit ventricular myocytes. Unexpectedly, they found that chronic exposure of cells to azithromycin potentiated the cardiac Na+ current, which they propose increased intracellular Na+ concentration and through Na+/Ca2+ exchange, led to dysregulation of intracellular Ca2+ concentration and the development of a syndrome they suggest most closely resembles catecholaminergic polymorphic ventricular tachycardia.15 Disappointingly, despite some effort, the authors were unable to identify the precise cause of augmented Na+ currents as their cell biological studies did not reveal an increase in expression or enhanced trafficking of the NaV1.5 sodium channel protein to the cell surface. Although they postulate that the effect may reflect altered post-translational modification or changes in protein–protein interactions, this remains speculative and a topic for further investigation.

Nonetheless, if we are to make significant strides realizing the promise of precision medicine, it is precisely these sorts of initial forays into mechanism that will enlighten and guide us. Precision medicine and big data go hand in hand, as associations between sequence variants or biomarkers and clinical phenotype are typically quite weak, and by necessity require exceedingly large databases to uncover. The translation of these statistical associations into clinically actionable health information is in many ways still dependent on a deliberate and at times tedious pursuit of mechanism. Although the authors’ claim that preclinical screening of new compounds might include an examination of their pharmacological effects on cardiac INa amplitude seems premature, their study does take us, albeit incrementally, toward the development of more precise and individualized targeting of drug therapy.

Sources of Funding

Research in the Fishman laboratory is supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute and the American Heart Association.

Disclosures

None.

Footnotes

  • The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

  • © 2017 American Heart Association, Inc.

References

  1. 1.↵
    Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press; 2011.
  2. 2.↵
    1. Collins FS,
    2. Varmus H
    . A new initiative on precision medicine. N Engl J Med. 2015;372:793–795. doi: 10.1056/NEJMp1500523.
    OpenUrlCrossRefPubMed
  3. 3.↵
    https://www.nih.gov/research-training/allofus-research-program. Accessed April 3, 2017.
  4. 4.↵
    https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed April 3, 2017.
  5. 5.↵
    1. Pollard CE,
    2. Valentin JP,
    3. Hammond TG
    . Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol. 2008;154:1538–1543. doi: 10.1038/bjp.2008.203.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Camm AJ
    . Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm. 2005;2(suppl 2):S23–S29. doi: 10.1016/j.hrthm.2004.09.019.
    OpenUrlPubMed
  7. 7.↵
    1. Ray WA,
    2. Murray KT,
    3. Hall K,
    4. Arbogast PG,
    5. Stein CM
    . Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881–1890. doi: 10.1056/NEJMoa1003833.
    OpenUrlCrossRefPubMed
  8. 8.↵
    https://www.fda.gov/Drugs/DrugSafety/ucm341822.htm. Accessed April 3, 2017.
  9. 9.↵
    1. Yang Z,
    2. Prinsen JK,
    3. Bersell KR,
    4. Shen W,
    5. Yermalitskaya L,
    6. Sidorova T,
    7. Luis PB,
    8. Hall L,
    9. Zhang W,
    10. Du L,
    11. Milne G,
    12. Tucker P,
    13. George AL,
    14. Campbell CM,
    15. Pickett RA,
    16. Shaffer CM,
    17. Chopra N,
    18. Yang T,
    19. Knollmann BC,
    20. Roden DM,
    21. Murray KT
    . Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythm Electrophysiol. 2017;10:e003560. doi: 10.1161/CIRCEP.115.003560.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Roden DM
    . Cellular basis of drug-induced torsades de pointes. Br J Pharmacol. 2008;154:1502–1507. doi: 10.1038/bjp.2008.238.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Sanguinetti MC,
    2. Jiang C,
    3. Curran ME,
    4. Keating MT
    . A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299–307.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Cubeddu LX
    . Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev. 2016;12:141–154.
    OpenUrl
  13. 13.↵
    1. Dumaine R,
    2. Antzelevitch C
    . Molecular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17:36–42.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Roden DM,
    2. Altman RB,
    3. Benowitz NL,
    4. Flockhart DA,
    5. Giacomini KM,
    6. Johnson JA,
    7. Krauss RM,
    8. McLeod HL,
    9. Ratain MJ,
    10. Relling MV,
    11. Ring HZ,
    12. Shuldiner AR,
    13. Weinshilboum RM,
    14. Weiss ST
    ; Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006;145:749–757. doi: 10.7326/0003-4819-145-10-200611210-00007.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Cerrone M,
    2. Napolitano C,
    3. Priori SG
    . Catecholaminergic polymorphic ventricular tachycardia: a paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation. Heart Rhythm. 2009;6:1652–1659. doi: 10.1016/j.hrthm.2009.06.033.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation: Arrhythmia and Electrophysiology
April 2017, Volume 10, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Drug-Induced Arrhythmias, Precision Medicine, and Small Data
    Glenn I. Fishman
    Circulation: Arrhythmia and Electrophysiology. 2017;10:e005208, originally published April 13, 2017
    https://doi.org/10.1161/CIRCEP.117.005208

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation: Arrhythmia and Electrophysiology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Drug-Induced Arrhythmias, Precision Medicine, and Small Data
    (Your Name) has sent you a message from Circulation: Arrhythmia and Electrophysiology
    (Your Name) thought you would like to see the Circulation: Arrhythmia and Electrophysiology web site.
  • Share on Social Media
    Drug-Induced Arrhythmias, Precision Medicine, and Small Data
    Glenn I. Fishman
    Circulation: Arrhythmia and Electrophysiology. 2017;10:e005208, originally published April 13, 2017
    https://doi.org/10.1161/CIRCEP.117.005208
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Mechanisms
    • Ion Channels/Membrane Transport
  • Arrhythmia and Electrophysiology
    • Sudden Cardiac Death
    • Electrophysiology
    • Arrhythmias

Circulation: Arrhythmia and Electrophysiology

  • About Circ Arrhythm Electrophysiol
  • Instructions for Authors
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom
Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451 
E-mail: circ@circulationjournal.org
Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer
  • You're the Cure

Online Communities

  • AFib Support
  • Empowered to Serve
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured